Catalyst
Slingshot members are tracking this event:
NewLink Genetics Presents Phase 1b Data of Indoximod in Combination With Gemcitabine/Nab-Paclitaxel for Patients With Metastatic Pancreatic Cancer That Show Encouraging Durable Responses With Delayed Pattern
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NLNK |
|
|
||||
Additional Information
In the Phase 1b portion of the trial, the combination therapy with indoximod had an objective response rate of 42 percent (5/12), including one CR. The MPACT study, which established gemcitabine/nab-paclitaxel as standard of care for patients with metastatic pancreatic cancer, demonstrated an objective response rate of 23 percent.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 22, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1b Data, Indoximod, Combination, Gemcitabine, Nab-paclitaxel, Phase 2 Metastatic Pancreatic Cancer Study, Ido Pathway Inhibitor, Response Rate
